all report title image
  • Published On : Dec 2022
  • Code : CMI5433
  • Industry : Biotechnology
  • Pages : 603
  • Formats :

Proteins are manufactured under guidelines that allow for their use as ancillary materials in cell therapy or further manufacturing processes. GMP proteins also come with extensive documentation and traceability, as well as additional quality control testing. Global GMP protein (E. coli) contract manufacturing market is estimated to be valued at US$ 685.8 million in 2022 and is expected to exhibit a CAGR of 9.7% during the forecast period (2022-2030).

Figure 1. Global GMP Protein (E. coli) Contract Manufacturing Market Share (%), by Application, 2022

GMP Protein (E. coli) Contract Manufacturing  | Coherent Market Insights

Global GMP Protein (E. coli) Contract Manufacturing Market- Drivers

Increasing research and development activities by key market players are expected to drive market growth over the forecast period. For instance, according to Alliance for Regenerative Medicine, 2020, approximately US$ 9.8 billion was raised in global financings for the cell and gene therapy sector in 2019. Moreover, according to the same source, in 2020, there were 572 ongoing regenerative medicine clinical trials in U.S. trial sites.

Increasing inorganic growth strategies by the key players to increase GMP grade protein production capacities is expected to drive market growth over the forecast period. For instance, in October 2021, Avid Bioservices, Inc., a dedicated biologics Contract Development and Manufacturing Organization (CDMO), announced that the company is increasing its CDMO service offering in the rapidly growing cell and gene therapy market. As part of this effort, the company is constructing a world-class, purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA, approximately five miles from Avid’s existing operations in Tustin, CA.

CMI table icon

GMP Protein (E. coli) Contract Manufacturing Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 685.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.7% 2030 Value Projection: US$ 1,439.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Cytokines, Growth Factors, EnzymesDNA polymerase (Protease, Trypsin, Nuclease (Benzonase, Cas9 Nucleases, Others), IVT Enzymes, Others), Hormones, Antigens, Others
  • By Application: Gene therapy, Cell therapy
  • By Method: In-Vivo, Ex-Vivo
  • By End User: Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, Others 
Companies covered:

Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne, Northway Biotech, Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma, FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus, F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.

Growth Drivers:
  • Increase in research and development activities by key market players
  • Increasing inorganic growth strategies by the key players to increase GMP grade protein production capacities
Restraints & Challenges:
  • High cost of GMP protein (E. coli) contract manufacturing products

Figure 2. Global GMP Protein (E. coli) Contract Manufacturing Market Share (%), by Region, 2022

GMP Protein (E. coli) Contract Manufacturing  | Coherent Market Insights

Global GMP Protein (E. coli) Contract Manufacturing Market – Impact of Coronavirus (COVID-19) Pandemic

Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. were disrupted due to lockdowns implemented by governments in the past few months, while countries such as Saudi Arabia, the UAE, Egypt, and others faced problems with the transportation of raw materials. The coronavirus or COVID-19 outbreak that started in Wuhan, China has spread across continents, affecting various industries globally. Supply of key materials had been severely disrupted due to forced quarantine and lack of labor and raw materials. As the link between regional warehouses was not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has affected the supply chain of the GMP protein (E. coli) contract manufacturing market.

Global GMP Protein (E. coli) Contract Manufacturing Market: Key Developments

In June 2021, Vectron Biosolutions AS, a company developing and marketing vector technologies for the biotechnology and life science industries, announced that it had raised US$ 2.7 million in a Series A financing round led by Dynamk Capital along with the acquisition of a bacterial secretion platform from T3S TECHNOLOGIES, INC., a biotechnology company. The acquisition of T3S Technologies’ secretion platform combined with Vectron’s core expression technology and additional financing will significantly help Vectron to reduce costs associated with the production of recombinant proteins or solutions to advance their challenging proteins to the market.

In November 2019, Abcam plc., a supplier of protein research tools to life scientists, announced a strategic partnership with BrickBio, Inc., a developer of a bioconjugation platform intended for research of site-specific modification of proteins. As a part of the partnership, Abcam plc. will have exclusive rights to the proprietary platform for introducing conjugation-ready sites into antibodies and other proteins in both mammalian and bacterial expression systems for the creation of novel conjugation-ready recombinant products for the research tools market. In addition, it will have the right to commercialize the platform across its recombinant antibody and protein portfolio for diagnostic purposes. BrickBio’s platform can site selectively modify proteins in a broad range of eukaryotic and bacterial cell lines. Using a proprietary engineered tRNA synthetase/tRNA pair, the platform can easily incorporate unnatural amino acids that can then be coupled to a second molecule for labeling or other research applications or to create protein-conjugate therapeutics including Antibody-Drug-Conjugates (ADCs).

Global GMP Protein (E. coli) Contract Manufacturing Market: Restraint

The major factors that hinder the growth of the global GMP protein (E. coli) contract manufacturing market include the high cost of recombinant protein manufacturing. The high cost involved in the production and research and development of recombinant proteins is expected to act as a restraint for the market growth. For instance, according to an article published by MDPI, a publisher of open-access scientific journals, in July 2019, the costs of a single clinical trial can vary from US$ 5 million for small, non-controlled orphan drug trials to US$ 350 million for large controlled studies. The median estimate is US$ 19 million. Moreover, according to an article published by ResearchGate, in July 2019, industrial proteins often have a retail price of tens of dollars per kilogram while recombinant proteins for medical use may cost billions of dollars per kilogram. Thus, the high cost of recombinant protein products and high cost involved in its manufacturing is expected to act as a restraint for the market growth.

Global GMP Protein (E. coli) Contract Manufacturing Market - Key Players

Major players operating in the global GMP protein (E. coli) contract manufacturing market include Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne , Northway Biotech , Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma , FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus , F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.

GMP Protein (E. coli)  may or may not be manufactured using animal-free processes depending on the characteristics of the protein. Recombinant Protein is a protein encoded by a gene recombinant DNA that has been cloned in a system that supports the expression of the gene and translation of messenger RNA. Modification of the gene by recombinant DNA technology can lead to the expression of a mutant protein. Proteins co-expressed in bacteria will not possess post-translational modifications, e.g. phosphorylation or glycosylation. Some of the recombinant proteins which were produced and commercialized in medications are Humulin, Hematrope, Avonex, Kogenate, Pulmozyme and others.

Market Dynamics

Increasing launches of products in the market is expected to drive the growth of the global GMP protein (E. coli) contract manufacturing market over the forecast period. For instance, in June 2022, AMSBIO, a provider of quality life science research reagents and services, announced the launch of its Stem Fit Protein range of recombinant proteins for cell therapy applications. The Stem Fit Protein range includes recombinant proteins that play key roles in differentiating Embryonic Stem (ES) and induced Pluripotent Cells (iPS) in the pancreas, heart, kidney, blood, and immune cells. Moreover, in September 2021, Aviva Systems Biology, a company providing antibodies, immunoassay kits, and recombinant proteins for life science research, announced the launch of its new Protein on Demand semi-custom GMP grade recombinant protein portfolio for life scientists conducting basic research and preclinical studies. The Protein on Demand portfolio of over 300,000 proteins allows rapid access to small- to mid-scale production of customized proteins for research teams.

Key features of the study:

  • This report provides an in-depth analysis of the global GMP protein (E. coli) contract manufacturing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global GMP protein (E. coli) contract manufacturing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne, Northway Biotech, Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma, FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus, F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global GMP protein (E. coli) contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GMP protein (E. coli) contract manufacturing market.

Detailed Segmentation:

  • Global GMP Protein (E. coli) Contract Manufacturing Market, By Product Type:
    • Cytokines
    • Growth Factors
    • Enzymes
      • DNA polymerase
      • Protease
      • Trypsin
      • Nuclease
        • Benzonase
        • Cas9 Nucleases
        • Others
      • IVT Enzymes
      • Others
    • Hormones
    • Antigens
    • Others
  • Global GMP Protein (E. coli) Contract Manufacturing Market, By Application:
    • Gene Therapy
    • Cell Therapy
  • Global GMP Protein (E. coli) Contract Manufacturing Market, By Method:
    • In-Vivo
    • Ex-Vivo
  • Global GMP Protein (E. coli) Contract Manufacturing Market, By End User:
    • Biotechnology and Pharmaceutical Companies
    • Academic & Research Institutes
    • Contract Research Organizations
    • Others
  • Global GMP Protein (E. coli) Contract Manufacturing Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Merck & Co., Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Thermo Fisher Scientific Inc.
    • Abcam plc
    • GenScript
    • Biomay AG
    • SOL GROUP
    • Proteintech Group, Inc.
    • Nordmark Pharma GmbH
    • Sino Biological, Inc.
    • Abnova Corporation
    • Eurofins Scientific
    • Arcline Investment Management LP
    • Abgenex
    • Xpress Biologics
    • Avid Bioservices Inc
    • Bio-Techne
    • Northway Biotech
    • Aldevron
    • Institut Mérieux
    • PerkinElmer Inc.
    • Creative BioMart
    • Profacgen
    • ProBioGen AG
    • 53Biologics
    • Leadgene Biomedical, Inc.
    • Ajinomoto Bio-Pharma
    • FUJIFILM Diosynth Biotechnologies
    • Avioq, Inc
    • Biovian Oy
    • KBI Biopharma
    • GTP Bioways
    • QIAGEN
    • Suzhou Novoprotein Technology Co., Ltd.
    • ACROBiosystems
    • Kactus
    • F. Hoffmann-La Roche Ltd.
    • Enzo Life Sciences, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global GMP protein (E. coli) contract manufacturing market is estimated to be valued at US$ 685.8 million in 2022 and is expected to exhibit a CAGR of 9.7% between 2022 and 2030.
Factors such as increasing research and development activities by key market players and increasing inorganic growth strategies by the key players to increase GMP grade protein production capacities are expected to drive the market.
Gene therapy is the leading application segment in the market.
The major factors hampering the market include the high cost of GMP protein (E. coli) contract manufacturing products.
Major players operating in the global GMP protein (E. coli) contract manufacturing market include Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne, Northway Biotech, Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma, FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus, F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo